Trastuzumab-containing regimens for metastatic breast cancer

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Balduzzi, Sara ^a   Mantarro, Stefania ^b   Guarneri, Valentina ^c   Tagliabue, Ludovica ^d   Pistotti, Vanna ^e   Moja, Lorenzo ^f   D'Amico, Roberto ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; LAPATINIB; LETROZOLE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TAXANE; TAXOID;

ANEMIA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DATA BASE; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL THERAPY; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; METASTATIC BREAST CANCER; MONOTHERAPY; MORTALITY RATE; OVERALL SURVIVAL; PATIENT CARE; PATIENT RISK; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; META ANALYSIS; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84902500977     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006242.pub2     Document Type: Review

References (65)

1. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Aktan G, et al.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Journal of Clinical Oncology 2012;30(21):2585-92.
2. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al.Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. Journal of Clinical Oncology 2010;28(7):1124-30.
3. O'Shaughnessy J, Blackwell KL, Burstein H, Storniolo AM, Sledge G, Baselga J, et al.A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [Abstract 1015]. American Society of Clinical Oncology. 2008.
4. Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, et al.Impact of lapatinib plus trastuzumab versus single agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Annals of Oncology 2011;22(12):2582-90.
5. Gasparini G, Gion M, Crivellari D, Morabito A, Rocco S, Spada A, et al.Interim analysis of a randomized phase IIb study of weekly paclitaxel (PCT) with or without trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC): Clinical and biological results [Abstract 138]. American Society of Clinical Oncology. 2003.
6. Gasparini G, Gion M, Mariani L, Papaldo P, Crivellari D, Filippelli G, et al.Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Research and Treatment 2007;101(3):355-65.
7. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, et al.Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial. The Breast 2012;21(1):27-33.
8. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of Clinical Oncology 2009;27(33):5529-37.
9. Extra J, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al.Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer [Abstract 555]. American Society of Clinical Oncology. 2005.
10. Extra JM, Cognetti F, Chan S, Maraninchi D, Snyder R, Lluch A, Tubiana-Hulin M, et al.Randomised phase II trial (M77001) of trastuzumab (Herceptin) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastatic breast cancer. European Journal of Cancer 2003;1:Abstract 672.
11. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of Clinical Oncology 2005;23(19):4265-74.
12. Baselga J, Kerrigan M, Burchmore M, Ash M. Health-related quality of life (HRQL) in women with HER2-overexpressing metastatic breast cancer (MBC) in a phase III study of Herceptin (R) plus chemotherapy versus chemotherapy alone. European Journal of Cancer 1999;35:Abstract 1276.
13. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients withHER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Annals of Oncology 2005;16(11):1772-7.
14. Eiermann W, on behalf of the International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Annals of Oncology 2001;12(1):57-62.
15. Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with trastuzumab (Herceptin) [Abstract]. Seminars in Oncology. 1999; Vol. 26, issue 4.
16. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects of treatment with Her2mab (trastuzumab/Herceptin™) plus chemotherapy (H+C) versus chemotherapy alone (C) on health-related quality of life (HRQL) in women with HER-2/neu-overexpressing metastatic breast cancer [Abstract 109]. American Society of Clinical Oncology. 2001.
17. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. Journal of Clinical Oncology 2002;20(14):3106-13.
18. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bayamonde A, et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 2001;344(11):783-92.
19. Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G. Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 2004;5(4):293-8.
20. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al.Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. Journal of Clinical Oncology 2004;22(6):1063-70.
21. Pirvulescu C, Uhlig M, von Minckwitz G. Trastuzumab improves the efficacy of chemotherapy in breast cancer treatment beyond progression. Breast Care 2008;3(5):364-5.
22. von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al.Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer 2011;47(15):2273-81.
23. von Minckwitz G, Zielinski C, Maarteense E, Vogel P, Schmidt M, Eidtmann H, et al.Capecitabine vs capecitabine+trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05) [Abstract 1025]. American Society of Clinical Oncology. 2008.
24. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al.Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. Journal of Clinical Oncology 2009;27(12):1999-2006.
25. Gelmon KA, Boyle F, Kaufman B, Huntsman D, Manikhas A, Di Leo A, et al.Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. Journal of Clinical Oncology 2012;30 Suppl:Abstract LBA 671.
26. Papaldo P, Fabi A, Ferretti G, Mottolese M, Cianciulli AM, Di Cocco B, et al.A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Annals of Oncology 2006;17(4):630-6. [PUBMED: 16410363]
27. Raff JP, Rajdev L, Malik U, Novik Y, Manalo JM, Negassa A, et al.Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clinical Breast Cancer 2004;4(6):420-7. [PUBMED: 15023243]
28. Apolone G, Joppi R, Bertele V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. British Journal of Cancer 2005;93(5):504-9.
29. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al.Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology 1996;14(3):737-44.
30. Bonifazi M, Franchi M, Rossi M, Moja L, Zambelli A, Zambon A, et al.Trastuzumab-related cardiotoxicity in early breast cancer: a cohort study. The Oncologist 2013;18(7):795-801. [PUBMED: 23823908]
31. Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Annals of Oncology 2005;16(11):1772-7.
32. Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, et al.American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. The Lancet Oncology 2013;14(13):1317-25.
33. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology 1999;17(9):2639-48.
34. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, et al.Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230(4730):1132-9.
35. D'Amico R, Bonafede E, Balduzzi S, Longo G, Guarneri V, Piacentini F, et al.Unplanned crossover in randomized controlled trials: consequences for efficacy and safety outcomes. Abstracts of the 19th Cochrane Colloquium; 2011 October 19-22; Madrid. Chichester: John Wiley & Sons, 2011.
36. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovitch C, Song F, et al.Evaluating non-randomised intervention studies. Health Technology Assessment 2003;7(27):iii-x, 1-173.
37. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
38. U.S. Food and Drug Administration. FDA Oncology Tools Approval Summary for Trastuzumab for HERCEPTIN. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist (accessed 5 Aug 2013).
39. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893-917.
40. Fleeman N, Bagust A, Boland A, Dickson R, Dundar Y, Moonan M, et al.Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2(HER2): a systematic review and economic analysis. Health Technology Assessment NIHR HTA programme 2011;15(42):1-93. [DOI: 10.3310/hta15420]
41. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer 2004;4(5):361-70.
42. Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, et al.Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. Journal of Clinical Oncology 2012;30(16):1989-95.
43. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendation. BMJ 2008;336:924-6.
44. Harris CA, Ward L, Dobbins TA, Drew AK, Pearson S. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Annals of Oncology 2011;22(6):1308-17.
45. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
46. Ioannidis JP, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ 2010;341:c4875. [PUBMED: 20837576]
47. Joppi R, Bertele V, Garattini S. Disappointing biotech. BMJ 2005;331(7521):895-7.
48. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al.Metastatic behavior of breast cancer subtypes. Journal of Clinical Oncology 2010;28(20):3271-7.
49. Liao C, Yin F, Huang P, Cao Y, Gao F. A meta-analysis of randomised controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer. The Breast Journal 2011;17(1):109-11.
50. Mannocci A, De Feo E, de Waure C, Specchia ML, Gualano MR, Barone C, et al.Use of trastuzumab in HER2-positive metastatic breast cancer beyond progression: a systematic review of published studies. Tumori 2010;96(3):385-91.
51. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. Journal of the National Cancer Institute 2008;100(24):1780-91. [PUBMED: 19066278]
52. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al.Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine 2007;357(26):2666-76.
53. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al.Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006243.pub2]
54. National Institute for Health and Care Excellence. Breast cancer - trastuzumab [TA 34]. London: National Institute for Health and Care Excellence (http://www.nice.org.uk/page.aspx?o=29274) (accessed 9 February 2006).
55. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
56. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. Journal of the National Cancer Institute 2004;96(10):739-49.
57. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al.Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of Oncology 2006;17:935-44.
58. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al.Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology 2013;9:2278-84.
59. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al.Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology 2002;20(5):1215-21.
60. Shadish WR, Cook TD, Campbell DT. Statistical conclusion validity and internal validity. Experimental and Quasi-experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin Company, 2002.
61. Simes RJ, Coates AS. Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed?. Journal of the National Cancer Institute. Monographs 2001;30:146-52. [PUBMED: 11773309]
62. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235(4785):177-82.
63. Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Gonçalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Research 2012;32(11):4655-62.
64. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al.First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001;61 Suppl 2:37-42.
65. Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD008941.pub2]